Specifically for the 177 patients with RA, the data revealed the following: 80.1% were using TNF-α inhibitors, with Etanercept (ETA) (41.5%) and Adalimumab (31.2%) being the most commonly prescribed. This evidence concerns the gene TNF and rheumatoid arthritis.